D3 Bio, a global, clinical-stage biotech company that counts Singapore’s Temasek Holdings and Boyu Capital among its investors, has closed a $62-million Series A+ round of financing to advance its pipeline of cancer drugs.
Continue Reading: Unlock Free Insights!
Stay updated with 3 free articles every month
Access our exclusive newsletters delivered to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
